Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 3, 2020
Event: Entry into a Material Definitive Agreement (Underwriting Agreement) for a public offering of common stock and pre-funded warrants.
Key Financial Metrics and Offering Details
- Securities Issued: 476,187 shares of common stock and pre-funded warrants to purchase 142,857 shares.
- Offering Price: $10.50 per share for common stock; $10.499 per pre-funded warrant.
- Estimated Net Proceeds: Approximately $5.9 million (after underwriting discounts, commissions, and estimated expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 92,856 shares.
- Use of Proceeds: Funding clinical research and development, and general working capital.
- Expected Closing Date: August 6, 2020.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics for the company.
Material Changes and Unusual Items
This filing reports a material capital raise event rather than operational performance changes. The primary material change is the execution of the Underwriting Agreement with Lake Street Capital Markets, LLC, pursuant to a shelf registration statement (File No. 333-229019) declared effective in February 2019.
Guidance, Outlook, and Risks
- Outlook: Management intends to utilize the net proceeds alongside existing cash and marketable securities to advance clinical research and development.
- Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may differ materially due to risks identified in the company's Form 10-Q for the period ended March 31, 2020, and the prospectus supplement.
- Warrant Restrictions: Pre-funded warrants are exercisable immediately but are subject to a beneficial ownership limitation of 9.99% (extendable to 19.99% with 61 days' notice).
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $5.9 million figure is an estimate assuming no exercise of the over-allotment option.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification obligations and termination provisions.
- Confirm the company's current cash position and burn rate to assess the runway provided by the new capital.
- Check subsequent filings for the exercise of the 30-day over-allotment option by the underwriters.